Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...

A medical device company has secured investment from the owner of the developer of Ozempic and a private equity firm, to ...

Novo Holdings and TA Associates have agreed to make an investment into Biocomposites.

Additional investment and resources will accelerate Biocomposites' international expansion and innovation in products for use in infection management HELLERUP, Denmark, LONDON and KEELE ...

Alcohol Justice has released its February 2025 eNews, a comprehensive roundup of the latest news, research, and advocacy ...

As Ramadan approaches, Also Sophia is proud to announce the launch of its latest Ramadan and Eid home decor collection, now ...

The FDA today declared the national deficit of GLP-1 diet drugs at an end. Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's ...

However, in June 2024 Novo Nordisk said it was recognising a loss of around 5.7 billion Danish crowns (US$800 million) in relation to the drug after adverse clinical trial results.

Spinnaker Trust raised its holdings in shares of Novo Nordisk A/S by 1.1% in the 3rd quarter. Spinnaker Trust now owns 9,615 shares of the company’s stock valued at $1,145,000 after buying an ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best drug stocks to buy now.